WuXi PharmaTech, PRA Restructure China JV

WuXi to provide clinical trial services for global trials subcontracted by PRA in China

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi PharmaTech (Cayman) Inc. and PRA Health Sciences have restructured their joint venture for the delivery of clinical trial management services in China, Macau and Hong Kong.   The portion of the joint venture in mainland China will now become a wholly owned subsidiary of WuXi, and the portion of the joint venture in Hong Kong will become a wholly owned subsidiary of PRA. In addition, PRA will retain its Strategic Solutions business in China and Hong Kong, which offers custom-built clinica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters